NanoString also beat analyst estimates on the top and bottom lines, and upped its revenue guidance for the year based primarily on collaboration revenues.
Sweden-based Immunovia is preparing to launch its first diagnostic — a liquid biopsy test for pancreatic cancer — in 2018.
The funding will be used in part to prepare an FDA submission for a clinical IVD pharmacogenomic test for its TruDx 2000 microarray platform.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.
The funding was supported by Finnish investment service company Kansalaisrahoitus Oy.
The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
The partners will work to offer panel-based genetic characterization for a US-based cohort.
The company will work with the nonprofit to create a test for resource-poor settings. It is also working under a new NIH grant to add antibiotic susceptibility testing to its system.
Roche said it will offer the microarray-based Harmony IVD kit and Ariosa Cell-Free DNA System (AcfS) software to laboratories outside the US.
The firm will adapt multiplex panels for prognosis of septic shock patients to its array-based portable diagnostic platform.
The firm will develop a platform to detect toxic algal blooms in freshwater and marine environments using its Array System and LightDeck technology.
NorthShore University HealthSystem is integrating decision support tools within it is EMR to help doctors use pharmacogenomics to personalize care.
The new test distinguishes Zika from other viruses in mosquito vectors and launches during an ongoing outbreak that has prompted new CDC guidelines.
The firm's core technology involves electrical charge-based isolation of bacterial and fungal cells from whole blood, with in-cartridge lysis and RT-PCR.
The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform.